# OnCo record nct06112379 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06112379/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06112379", "NCT06112379" ;
  schema:name "A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer"@en ;
  schema:alternateName "TROPION-Breast04"@en ;
  schema:description "A phase 3 trial of Durvalumab, Pembrolizumab, Doxorubicin, Epirubicin, Cyclophosphamide and Carboplatin in HR-positive / HER2-negative breast cancer, run by AstraZeneca, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06112379/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06112379>, <https://doi.org/10.1177/17588359251316176> ;
  onco:status "active" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2023-11-14" ;
  onco:cancers <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/tnbc-early/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/epirubicin/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/carboplatin/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/>, <https://onco.cc/companies/daiichi-sankyo/> .